Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study.

Br J Cancer · 2017 · PMC5482736 · PMID 28399112

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an unexpected trendno p-value reported

In the primary analysis of NORDIC-VII an unexpected trend towards increased PFS was found in patients with tumours harbouring KRAS (exon 2) mutations who received FLOX plus cetuximab, as compared to FLOX alone (arm B vs arm A).

also in 275 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.